All About Us

Overview

In 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the United States and 606,520 people died from the disease. Worldwide, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020

​

OncoStem Biotherapeutics is developing a new class of potentially less toxic, personalized, small molecule oral cancer drugs. 

Our Story

This story is not a story about OncoStem Biotherapeutics. Ultimately, It is about those who have had to contend with this dreadful disease.

Let me paraphrase Kubler Ross: The most precious people oncologists have known are those who have known defeat from this disease, who have known struggle, who have known loss, and yet still somehow found their way out of the devastating cost we pay when dealing with cancer.

​

     OncoStem Biotherapeutics, is a novel, small startup, cancer drug development Biotech Company. It is embolden to change the way we treat cancer. 

     OncoStem is proposing a whole new approach to cancer drug development and treatment. 

It is time to take a more logical, rational, but scientific approach in the treatment of cancer.  OncoStem Biotherapeutics has applied Bioinformatics to Systems Biology, Genomics, and Network Theory to identify a group of unique genetic biomarkers critical to cancer growth and metastasis, and specific for any individual’s unique cancer. OncoStem possesses a proprietary database of such biomarkers. The protein products of these cancer biomarkers are already commercially available for the establishment of inhibitory assays for the immediate identification of drug Hits and subsequent drug Hit Leads for the development of a whole new class of oral, targeted anti-cancer drugs.

OncoStem Biotherapeutics is applying Insilico Medicine's novel AI platform to its drug development process shifting targeted cancer therapy and drug development into an exciting paradigm.

​

​

​